AstraZeneca Pharma India Ltd, a prominent biopharmaceutical company in India and a subsidiary of AstraZeneca Plc, headquartered in Cambridge, UK, has been at the forefront of advancing healthcare since its establishment in 1979. Headquartered in Bengaluru, Karnataka, the company is dedicated to leveraging science and innovation to deliver transformative medicines that enhance the health and lives of people across India. AstraZeneca Pharma India Ltd operates across key therapeutic areas, including oncology, cardiovascular, renal, metabolic diseases, respiratory, and immunology, addressing some of the most pressing medical challenges of our time. Renowned for its strong focus on research and development, the company strives to meet unmet medical needs by introducing cutting-edge therapies to the market. Beyond its core business of manufacturing, distributing, and marketing pharmaceutical products, AstraZeneca Pharma India actively collaborates with healthcare providers, government bodies, and patient advocacy groups to improve access to treatments. It also undertakes various initiatives to bolster patient education and strengthen healthcare infrastructure, underscoring its commitment to advancing the overall healthcare ecosystem in India.
Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
Promoters + | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
FIIs + | 2.66% | 2.73% | 2.79% | 2.90% | 2.92% |
DIIs + | 2.76% | 3.77% | 4.99% | 5.08% | 5.21% |
Public + | 19.57% | 18.50% | 17.21% | 17.02% | 16.85% |
No. of Shareholders | 29,032 | 29,418 | 27,169 | 27,615 | 27,322 |
The shareholding pattern of AstraZeneca Pharma India Ltd from December 2023 to December 2024 reflects stability and evolving investor confidence. Promoters maintained a consistent 75% stake throughout the period, showcasing their unwavering commitment. Foreign Institutional Investors (FIIs) gradually increased their holdings from 2.66% to 2.92%, while Domestic Institutional Investors (DIIs) showed significant growth, rising from 2.76% to 5.21%, highlighting strong domestic and international interest in the company. Public shareholding declined from 19.57% to 16.85%, indicating a shift towards institutional ownership. The number of shareholders also saw a slight consolidation, reducing from 29,032 to 27,322, suggesting a more concentrated and potentially strategic shareholder base. These trends underscore AstraZeneca Pharma India Ltd’s appeal as a stable and attractive investment option for institutional stakeholders.
Latest News on AstraZeneca Pharma India
AstraZeneca Pharma India Ltd has recently achieved a significant milestone by securing approval from India’s drug regulatory authority to import and sell sodium zirconium cyclosilicate powder, marketed under the brand name Lokelma. This innovative medication is specifically designed to treat hyperkalaemia, a medical condition marked by abnormally high potassium levels in the blood, which can lead to serious cardiovascular and renal complications if left untreated. Lokelma represents a vital addition to AstraZeneca’s portfolio, addressing a critical therapeutic need in the management of electrolyte imbalances. This approval underscores the company’s commitment to bringing advanced, science-driven treatments to the Indian market, enhancing its contribution to improving patient outcomes in the region.
Below are the trading platforms that you can use to purchase AstraZeneca Pharma India shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
When | Maximum Price | Minimum Price |
April 2025 | 8,117.77 | 6,244.44 |
May 2025 | 7,881.33 | 6,062.56 |
June 2025 | 8,235.99 | 6,335.38 |
July 2025 | 8,074.50 | 6,211.15 |
August 2025 | 8,324.23 | 6,403.25 |
September 2025 | 8,424.12 | 6,480.09 |
October 2025 | 8,643.14 | 6,648.57 |
November 2025 | 8,859.22 | 6,814.79 |
December 2025 | 9,257.89 | 7,121.45 |
As we move through 2025, AstraZeneca Pharma India’s share price is expected to show significant fluctuations. In April, the maximum share price may reach ₹8,117.77, while the minimum share price could be around ₹6,244.44. By December, the maximum share price is projected to rise to ₹9,257.89, with the minimum share price anticipated at ₹7,121.45.
When | Maximum Price | Minimum Price |
January 2026 | 9,535.62 | 7,335.10 |
February 2026 | 9,297.23 | 7,151.72 |
March 2026 | 9,483.18 | 7,294.75 |
April 2026 | 9,676.71 | 7,443.62 |
May 2026 | 9,580.90 | 7,369.93 |
June 2026 | 9,820.43 | 7,554.17 |
July 2026 | 9,627.87 | 7,406.05 |
August 2026 | 9,925.64 | 7,635.11 |
September 2026 | 10,124.15 | 7,787.81 |
October 2026 | 10,387.38 | 7,990.29 |
November 2026 | 10,647.06 | 8,190.05 |
December 2026 | 10,913.24 | 8,394.80 |
In 2026, AstraZeneca Pharma India’s share price is projected to exhibit a consistent upward trajectory. In January, the maximum share price is expected to reach ₹9,535.62, with the minimum price around ₹7,335.10. By December, the share price is anticipated to rise further, with a maximum of ₹10,913.24 and a minimum of ₹8,394.80.
When | Maximum Price | Minimum Price |
January 2027 | 11,022.37 | 8,478.75 |
February 2027 | 11,305.00 | 8,696.15 |
March 2027 | 11,745.89 | 9,035.30 |
April 2027 | 11,515.58 | 8,858.14 |
May 2027 | 11,180.17 | 8,600.13 |
June 2027 | 11,683.28 | 8,987.14 |
July 2027 | 11,454.20 | 8,810.92 |
August 2027 | 11,808.45 | 9,083.42 |
September 2027 | 12,221.75 | 9,401.34 |
October 2027 | 12,539.51 | 9,645.78 |
November 2027 | 12,853.00 | 9,886.92 |
December 2027 | 13,174.33 | 10,134.10 |
When | Maximum Price | Minimum Price |
January 2028 | 13,437.81 | 10,336.78 |
February 2028 | 13,782.37 | 10,601.82 |
March 2028 | 14,319.88 | 11,015.30 |
April 2028 | 14,039.10 | 10,799.31 |
May 2028 | 13,630.20 | 10,484.77 |
June 2028 | 14,243.55 | 10,956.58 |
July 2028 | 13,964.27 | 10,741.75 |
August 2028 | 14,396.15 | 11,073.96 |
September 2028 | 14,900.02 | 11,461.55 |
October 2028 | 15,287.42 | 11,759.55 |
November 2028 | 15,669.61 | 12,053.54 |
December 2028 | 16,061.35 | 12,354.88 |
When | Maximum Price | Minimum Price |
January 2029 | 16,382.57 | 12,601.98 |
February 2029 | 16,802.64 | 12,925.11 |
March 2029 | 17,457.94 | 13,429.19 |
April 2029 | 17,115.63 | 13,165.87 |
May 2029 | 16,617.12 | 12,782.40 |
June 2029 | 17,364.89 | 13,357.60 |
July 2029 | 17,024.40 | 13,095.69 |
August 2029 | 17,550.93 | 13,500.71 |
September 2029 | 18,165.21 | 13,973.24 |
October 2029 | 18,637.50 | 14,336.54 |
November 2029 | 19,103.44 | 14,694.95 |
December 2029 | 19,581.03 | 15,062.33 |
When | Maximum Price | Minimum Price |
January 2030 | 19,972.65 | 15,363.57 |
February 2030 | 20,484.77 | 15,757.51 |
March 2030 | 21,283.67 | 16,372.06 |
April 2030 | 20,866.35 | 16,051.04 |
May 2030 | 20,258.59 | 15,583.53 |
June 2030 | 21,170.22 | 16,284.79 |
July 2030 | 20,755.12 | 15,965.48 |
August 2030 | 21,397.03 | 16,459.26 |
September 2030 | 22,145.93 | 17,035.33 |
October 2030 | 22,721.72 | 17,478.25 |
November 2030 | 23,289.77 | 17,915.20 |
December 2030 | 23,872.01 | 18,363.08 |
As we progress through 2030, AstraZeneca Pharma India’s share price is anticipated to show substantial growth. In January, the maximum share price is expected to reach ₹19,972.65, with the minimum price around ₹15,363.57. By December, the share price is projected to climb significantly, with a maximum of ₹23,872.01 and a minimum of ₹18,363.08. These figures highlight AstraZeneca Pharma India’s potential to sustain strong market performance throughout the year.
Financial Condition of AstraZeneca Pharma India
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
Sales + | 832 | 814 | 806 | 1,003 | 1,296 | 1,619 |
Expenses + | 711 | 678 | 719 | 838 | 1,111 | 1,402 |
Operating Profit | 121 | 135 | 86 | 165 | 184 | 217 |
OPM % | 15% | 17% | 11% | 16% | 14% | 13% |
Other Income + | 13 | 13 | 15 | -14 | 51 | -58 |
Interest | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 19 | 20 | 17 | 16 | 15 | 26 |
Profit before tax | 114 | 127 | 83 | 134 | 220 | 132 |
Tax % | 37% | 27% | 26% | 26% | 26% | |
Net Profit + | 72 | 93 | 62 | 99 | 162 | 97 |
EPS in Rs | 28.88 | 37.32 | 24.64 | 39.72 | 64.6 | 38.78 |
Dividend Payout % | 3% | 5% | 41% | 40% | 37% |
AstraZeneca Pharma India has demonstrated a strong financial performance from March 2020 to March 2024, with significant growth across key metrics. The company’s sales revenue has risen steadily from ₹832 crore in March 2020 to ₹1,296 crore in March 2024, with a trailing twelve-month (TTM) figure of ₹1,619 crore. This strong growth highlights AstraZeneca Pharma India’s expanding market presence and increasing demand for its pharmaceutical products. Concurrently, expenses have increased from ₹711 crore in March 2020 to ₹1,111 crore in March 2024, reflecting investments to support this growth trajectory. Despite fluctuations, the operating profit has also grown from ₹121 crore to ₹184 crore over the same period, supported by an efficient expense management strategy.
The company’s profitability metrics indicate resilience despite challenges. The OPM (Operating Profit Margin) has varied between 11% and 17% over the years, settling at 14% in March 2024. Other income showed variability, with a significant peak at ₹51 crore in March 2024, though it reflected a negative value in the TTM due to specific adjustments. Profit before tax saw a consistent increase, rising from ₹114 crore in March 2020 to ₹220 crore in March 2024, showcasing AstraZeneca Pharma India’s robust financial operations. With a stable tax rate of around 26%, the company’s net profit surged from ₹72 crore in March 2020 to ₹162 crore in March 2024, reinforcing its strong performance.
Shareholder returns have also improved significantly, as reflected in the EPS (Earnings Per Share), which rose from ₹28.88 in March 2020 to ₹64.6 in March 2024. The company maintained a prudent dividend payout ratio, peaking at 41% in March 2022 and stabilizing at 37% in March 2024, ensuring a balance between rewarding shareholders and retaining earnings for future growth.
FAQs
What Is the Market Value of AstraZeneca Pharma India?
The market capitalization (Market Cap) of AstraZeneca Pharma India as of 15th March 2025 is ₹19,189 Crores.
As of 15th March 2025, the current share price of AstraZeneca Pharma India is ₹7,676.
What Is the Stock PE Ratio of AstraZeneca Pharma India?
The stock P/E ratio for AstraZeneca Pharma India is 114.
The Share Price target of AstraZeneca Pharma India is expected to reach ₹23,872.01 by the end of 2030.
Also, check other Companies Share Price Targets:
- Ahluwalia Contracts (India) Share Price Target 2025, 2026 to 2030
- Sundaram Finance Share Price Target 2025, 2026 to 2030
- Kovai Medical Center & Hospital Share Price Target 2025, 2026 to 2030
Conclusion
AstraZeneca Pharma India Ltd continues to lead in healthcare innovation, backed by strong financial performance, strategic collaborations, and a commitment to patient-centric solutions. The company recently launched Lokelma, a groundbreaking treatment for hyperkalaemia, further enhancing its diverse portfolio. This addition underscores AstraZeneca’s focus on addressing critical medical challenges in India. With its dedication to advancing therapies across oncology, cardiovascular, and respiratory domains, alongside strategic partnerships and investments in cutting-edge research, AstraZeneca Pharma India Ltd is well-positioned for sustained growth and greater impact in India’s healthcare landscape.
What did we learn?
- 1 Shareholdings Patterns of Astrazeneca Pharma India
- 2 Latest News on AstraZeneca Pharma India
- 3 How to Purchase AstraZeneca Pharma India Shares in India?
- 4 AstraZeneca Pharma India Share Price Target 2025, 2026 to 2030
- 4.1 AstraZeneca Pharma India Share Price Target 2025
- 4.2 AstraZeneca Pharma India Share Price Prediction 2026
- 4.3 AstraZeneca Pharma India Share Price Target 2027
- 4.4 AstraZeneca Pharma India Share Price Prediction 2028
- 4.5 AstraZeneca Pharma India Share Price Target 2029
- 4.6 AstraZeneca Pharma India Share Price Target 2030
- 5 Financial Condition of AstraZeneca Pharma India
- 6 FAQs
- 7 Conclusion